Nivolumab: all 1,113 studies that test it

Page 5 of 12. Open to participants first (176), then studies with results posted, then the rest; newest registration first within each.

• A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a KidneyCompletedNCT03138512Phase 3Results posted
• A Study of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients With Advanced Stage Classical Hodgkin Lymphoma, Who Are Relapsed/ Refractory or Who Are Not Eligible for Autologous Stem Cell Transplant,TerminatedNCT03138499Phase 3Results posted
• CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With NivolumabCompletedNCT03123783Phase 1/2Results posted
• Ibrutinib, Nivolumab and Blinatumomab in Richter TransformationTerminatedNCT03121534Phase 2Results posted
• Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell CarcinomaCompletedNCT03117309Phase 2Results posted
• Study of ONO-4538 in Non-Squamous Non-Small Cell Lung Cancer (TASUKI-52)CompletedNCT03117049Phase 3Results posted
• First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Participants With Advanced Solid TumorsTerminatedNCT03110107Phase 1/2Results posted
• Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeCompletedNCT03092674Phase 2/3Results posted
• Safety Study of Nivolumab to Treat Advanced or Metastatic Non-small Cell Lung CancerCompletedNCT03090737Phase 2Results posted
• Neo-Adjuvant Immunotherapy With Nivolumab for Non Small Cell Lung Cancer PatientsCompletedNCT03081689Phase 2Results posted
• Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell LymphomaTerminatedNCT03075553Phase 2Results posted
• A Trial to Evaluate the Safety and Efficacy of the Combination of the Oncolytic Immunotherapy Pexa-Vec With the PD-1 Receptor Blocking Antibody Nivolumab in the First-line Treatment of Advanced Hepatocellular Carcinoma (HCC)TerminatedNCT03071094Phase 1/2Results posted
• Phase I/Ib Study of Nivolumab & Veliparib in Patients With Advanced Solid Tumors & LymphomaCompletedNCT03061188Phase 1Results posted
• Nivolumab & Brentuximab Vedotin Consolidation After Autologous SCT in Patients With High-Risk Classical Hodgkin LymphomaActive, not recruitingNCT03057795Phase 2Results posted
• Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing NephrectomyActive, not recruitingNCT03055013Phase 3Results posted
• Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney CancerTerminatedNCT03050060Phase 2Results posted
• Nivolumab and Metformin Hydrochloride in Treating Patients With Stage III-IV Non-small Cell Lung Cancer That Cannot Be Removed by SurgeryStatus unknownNCT03048500Phase 2Results posted
• Combination Therapy With Nivolumab and PD-L1/IDO Peptide Vaccine to Patients With Metastatic MelanomaCompletedNCT03047928Phase 1/2Results posted
• Ipilimumab + Nivolumab w/Thoracic Radiotherapy for Extensive-Stage Small Cell Lung CancerCompletedNCT03043599Phase 1/2Results posted
• Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 InhibitorTerminatedNCT03041181Phase 2Results posted
• Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial CancerActive, not recruitingNCT03036098Phase 3Results posted
• Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced MelanomaCompletedNCT03033576Phase 2Results posted
• An Investigational Immuno-Therapy Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell CarcinomaCompletedNCT03029780Phase 2Results posted
• Trial of Nivolumab as a Novel Neoadjuvant Pre-Surgical Therapy for Locally Advanced Oral Cavity CancerCompletedNCT03021993Phase 2Results posted
• Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HLActive, not recruitingNCT03016871Phase 2Results posted
• Sitravatinib and Nivolumab in Treating Patients With Advanced or Metastatic Kidney CancerCompletedNCT03015740Phase 1/2Results posted
• An Exploratory Study of the Effects of Nivolumab Combined With Ipilimumab in Patients With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)CompletedNCT03001882Phase 2Results posted
• A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC)CompletedNCT02998528Phase 3Results posted
• Phase Ib/II Trial of Interleukin-2 and PD-1 Checkpoint Inhibitor, Nivolumab In Metastatic Clear Cell Renal Cell CancerCompletedNCT02989714Phase 1/2Results posted
• A Study of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMate 650)CompletedNCT02985957Phase 2Results posted
• A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell CancerCompletedNCT02982954Phase 4Results posted
• A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With IpilimumabTerminatedNCT02978443Phase 2Results posted
• Study of Combination of Ipilimumab and Nivolumab in Patients With MelanomaCompletedNCT02970981Phase 2Results posted
• A Study of Nivolumab Safety and Pharmacokinetics in Patients With Severe Sepsis or Septic Shock.CompletedNCT02960854Phase 1Results posted
• H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other GliomasCompletedNCT02960230Phase 1/2Results posted
• Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic MutationsTerminatedNCT02949843Phase 2Results posted
• Ipilimumab and Nivolumab in Leptomeningeal MetastasesCompletedNCT02939300Phase 2Results posted
• A Study to Test Combination Treatments in Participants With Advanced Gastric CancerCompletedNCT02935634Phase 2Results posted
• A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line TreatmentCompletedNCT02927769Phase 2Results posted
• Addition of X4P-001 to Nivolumab Treatment in Participants With Renal Cell CarcinomaTerminatedNCT02923531Phase 1/2Results posted
• A Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid TumorsCompletedNCT02913313Phase 1/2Results posted
• A Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With MelanomaCompletedNCT02905266Phase 3Results posted
• JTX-2011 Alone and in Combination With Anti-PD-1 or Anti-CTLA-4 in Subjects With Advanced and/or Refractory Solid TumorsCompletedNCT02904226Phase 1/2Results posted
• A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering MyelomaCompletedNCT02903381Phase 2Results posted
• Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma PatientsCompletedNCT02899299Phase 3Results posted
• Ibrutinib and Nivolumab in Treating Patients With Previously-Treated Metastatic Kidney CancerCompletedNCT02899078Phase 1/2Results posted
• Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast CancerTerminatedNCT02892734Phase 2Results posted
• Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic LeukemiaActive, not recruitingNCT02879695Phase 1Results posted
• Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction CancerCompletedNCT02872116Phase 3Results posted
• An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced CancersCompletedNCT02869789Phase 4Results posted
• Phase 2 Study of Nivolumab in Solid Tumors Induced by Prior Radiation ExposureTerminatedNCT02864316Phase 2Results posted
• A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) TherapyCompletedNCT02864251Phase 3Results posted
• A Study Evaluating TAS-102 Plus Nivolumab in Patients With MSS CRCCompletedNCT02860546Phase 2Results posted
• A Safety and Efficacy Study of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellular Carcinoma (HCC)CompletedNCT02859324Phase 1/2Results posted
• A Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Relapsed/Refractory Primary Testicular Lymphoma (PTL)CompletedNCT02857426Phase 2Results posted
• Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung CancerTerminatedNCT02846792Phase 1/2Results posted
• Nivolumab and Yttrium Y 90 Glass Microspheres in Treating Patients With Advanced Liver CancerCompletedNCT02837029Phase 1Results posted
• A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid TumorsTerminatedNCT02834247Phase 1Results posted
• A Study of Pre-Operative Treatment With Cryoablation and Immune Therapy in Early Stage Breast CancerCompletedNCT02833233Not applicableResults posted
• An Open Label Investigational Immuno-therapy Trial of Nivolumab in Cancers That Are Advanced or Have SpreadCompletedNCT02832167Phase 2Results posted
• Trial of Radiation and Gene Therapy Before Nivolumab for Metastatic Non-Small Cell Lung Carcinoma and Uveal MelanomaTerminatedNCT02831933Phase 2Results posted
• Study of Nivolumab in Patients With Advanced Refractory Biliary Tract CancersCompletedNCT02829918Phase 2Results posted
• TG4010 and Nivolumab in Patients With Lung CancerCompletedNCT02823990Phase 2Results posted
• Nivolumab and Dasatinib in Treating Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic LeukemiaTerminatedNCT02819804Phase 1Results posted
• Nivolumab and Stereotactic Ablative Radiation Therapy (SAbR) for Metastatic Clear Cell Renal Cell CarcinomaTerminatedNCT02781506Phase 2Results posted
• Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC)TerminatedNCT02771626Phase 1/2Results posted
• Cisplatin and Etoposide Plus Radiation Followed By Nivolumab/Placebo For Locally Advanced NSCLCTerminatedNCT02768558Phase 3Results posted
• Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin LymphomaActive, not recruitingNCT02758717Phase 2Results posted
• Combination Therapy for Patients With Untreated Metastatic Pancreatic Ductal AdenocarcinomaCompletedNCT02754726Phase 2Results posted
• An Investigational Immuno-therapy Study of Experimental Medication BMS-986179 Given Alone and in Combination With NivolumabCompletedNCT02754141Phase 1/2Results posted
• An Investigational Immuno-therapy Study of Nivolumab or Placebo in Participants With Resected Esophageal or Gastroesophageal Junction CancerCompletedNCT02743494Phase 3Results posted
• Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckCompletedNCT02741570Phase 3Results posted
• An Investigational Immuno-Therapy Study of Experimental Medication BMS-986178 by Itself or in Combination With Nivolumab and/or Ipilimumab in Participants With Solid Cancers That Are Advanced or Have SpreadCompletedNCT02737475Phase 1/2Results posted
• Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor TherapyCompletedNCT02731729Phase 2Results posted
• An Investigational Immuno-therapy Study of Nivolumab, Pomalidomide and Dexamethasone Combinations in Patients With Multiple MyelomaCompletedNCT02726581Phase 3Results posted
• Nivolumab in Treating Patients With Metastatic Adrenocortical CancerTerminatedNCT02720484Phase 2Results posted
• A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic MelanomaCompletedNCT02714218Phase 3Results posted
• A Dose Frequency Optimization,Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer Who Received Up to 12 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 WeeksCompletedNCT02713867Phase 3Results posted
• Study of Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid TumorsCompletedNCT02705105Phase 1/2Results posted
• Check Point Inhibition After Autologous Stem Cell Transplantation in Patients at High Risk of Post Transplant RecurrenceTerminatedNCT02681302Phase 1/2Results posted
• An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)CompletedNCT02667587Phase 3Results posted
• Pilot Study of the Safety/Efficacy of Combination Checkpoint Blockade + External Beam Radiotherapy in Stage IV MelanomaCompletedNCT02659540Phase 1Results posted
• Adjuvant Nivolumab & Low Dose Ipilimumab for Stage III & Resected Stage IV MelanomaActive, not recruitingNCT02656706Phase 2Results posted
• An Open-Label Phase II Study of Nivolumab or Nivolumab/Ipilimumab in Adult Participants With Progessive/ Recurrent MeningiomaActive, not recruitingNCT02648997Phase 2Results posted
• An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the CancerCompletedNCT02632409Phase 3Results posted
• Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/LymphomaCompletedNCT02631746Phase 2Results posted
• An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)CompletedNCT02617589Phase 3Results posted
• Efficacy Study of Nivolumab Compared to Docetaxel in Subjects Previously Treated With Advanced or Metastatic Non Small Cell Lung CancerCompletedNCT02613507Phase 3Results posted
• Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS)TerminatedNCT02599649Phase 2Results posted
• An Investigational Immuno-therapy Study of Experimental Medication BMS-986156, Given by Itself or in Combination With Nivolumab in Patients With Solid Cancers or Cancers That Have Spread.CompletedNCT02598960Phase 1/2Results posted
• An Investigational Immuno-therapy Safety Trial of Nivolumab in Patients With Advanced or Metastatic Renal Cell CarcinomaCompletedNCT02596035Phase 4Results posted
• A Study of Safety, Tolerability and Pharmacokinetics of Nivolumab in Chinese Subjects With Previously Treated Advanced or Recurrent Solid TumorsCompletedNCT02593786Phase 1/2Results posted
• An Investigational Immuno-therapy Safety and Effectiveness Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin LymphomasCompletedNCT02581631Phase 1/2Results posted
• An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular CarcinomaCompletedNCT02576509Phase 3Results posted
• A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)CompletedNCT02574078Phase 1/2Results posted
• A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin LymphomaCompletedNCT02572167Phase 1/2Results posted
• Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal CancerCompletedNCT02569242Phase 3Results posted
• Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260)CompletedNCT02553642Phase 2Results posted
• An Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based ChemotherapyCompletedNCT02538666Phase 3Results posted
• Nivolumab in AML in Remission at High Risk for RelapseCompletedNCT02532231Phase 2Results posted

← Nivolumab overview